A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma
- 10 July 2006
- journal article
- phase ii-studies
- Published by Springer Science and Business Media LLC in Investigational New Drugs
- Vol. 24 (6), 543-546
- https://doi.org/10.1007/s10637-006-9208-z
Abstract
The aim of this study was to determine the antitumor activity of 17-(Allylamino)-17-demethoxyge-ldanamycin (17-AAG), a heat shock protein 90(hsp90) inhibitor in patients with metastatic papillary renal cell carcinoma (RCC) or metastatic clear cell RCC. Eligible patients were divided into 2 cohorts based on histological subtype: papillary or clear cell RCC. All patients had advanced RCC with measurable disease, a Karnofsky performance status of at least 70, and no evidence of brain metastases. Twelve patients with clear cell RCC and 8 patients with papillary RCC were treated with 17-AAG on this phase II trial. 17-AAG was given intravenously at 220 mg/m2 twice weekly for 2 weeks followed by a week of rest. Cycle length was 21 days. No patient in either cohort achieved a complete or partial response. Toxicities included elevated liver function tests, optic neuritis, dyspnea, fatigue, and gastrointestinal side effects. Six of the 20 patients required dose reduction. At the dose and schedule used in this trial, 17-AAG did not achieve objective response in the treatment of clear cell or papillary renal cell carcinoma patients.Keywords
This publication has 15 references indexed in Scilit:
- Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell CarcinomaJournal of Clinical Oncology, 2006
- Phase I and Pharmacologic Study of 17-(Allylamino)-17-Demethoxygeldanamycin in Adult Patients With Solid TumorsJournal of Clinical Oncology, 2005
- Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients With Advanced CancerJournal of Clinical Oncology, 2005
- Therapeutic Options for Variant Renal CancerClinical Cancer Research, 2004
- 17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma modelsAnti-Cancer Drugs, 2004
- The Genetic Basis of Cancer of the KidneyJournal of Urology, 2003
- Hsp90 Regulates a von Hippel Lindau-independent Hypoxia-inducible Factor-1α-degradative PathwayOnline Journal of Public Health Informatics, 2002
- Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2Oncogene, 2002
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Novel mutations of the MET proto-oncogene in papillary renal carcinomasOncogene, 1999